Liver Fibrosis, Hepatic Function Panel with Fibrosis‑4 (FIB‑4) Index

Also known as: FIB4, NASH, NAFLD, Nonalcoholic, Fatty

Clinical Use

Use

The Liver Fibrosis, Hepatic Function Panel with Fibrosis‑4 (FIB‑4) Index is intended as a non‑invasive assessment tool combining standard hepatic function biomarkers (ALT, AST, platelet count) with patient age to yield a FIB‑4 score. It serves to help evaluate risk of advanced liver fibrosis in patients at risk for metabolic dysfunction‑associated steatotic liver disease (MASLD). Higher FIB‑4 scores may prompt further evaluation or specialist referral. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/about-our-tests/metabolic-dysfunction-associated-steatotic-liver-disease/fib-4-index-panel?utm_source=openai))

Special Instructions

Not provided.

Limitations

This panel is an initial risk assessment tool and not diagnostic. It does not directly diagnose MASLD or advanced fibrosis but indicates risk level; elevated FIB‑4 (e.g., ≥1.30) may require follow‑up testing such as the Enhanced Liver Fibrosis (ELF) test. Clinical limitations include possible reduced accuracy in certain age groups (e.g., 65), and it should be interpreted within the context of clinical and demographic factors. ([questhealth.com](https://www.questhealth.com/product/advanced-fatty-liver-disease-panel/12734M.html?utm_source=openai))

Test Details